Breaking News Instant updates and real-time market news.

ABEO

Abeona Therapeutics

$18.50

1.1 (6.32%)

08:46
10/06/17
10/06
08:46
10/06/17
08:46

Abeona Therapeutics announces top-line one year data from ABO-102 MPS IIIA trial

Abeona Therapeutics announced one year data from Cohort 1 of the ongoing ABO-102 Phase 1/2 trial for Sanfilippo syndrome Type A, or MPS IIIA. The results demonstrated robust and durable clinical effects achieved one year post-administration, with significant reductions in biopotency and biophysical measures, preservation of deep brain architecture, and stabilization across multiple neurocognitive assessments reported in comparison to untreated control subjects. The ongoing gene therapy trial for ABO-102, or AAV-SGSH, is utilizing a single intravenous injection for treatment of subjects with Sanfilippo syndrome Type A, or MPS IIIA, a rare autosomal-recessive lysosomal storage disease. Results were announced during the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa being held this week in La Jolla, CA. Per the design of the clinical trial, subjects received a single, intravenous injection of ABO-102 to deliver the AAV viral vector systemically throughout the body to introduce a corrective copy of the gene that underlies the cause of the MPS IIIA disease. Subjects were evaluated at multiple time points post-injection for safety assessments and initial signals of biopotency and clinical activity. Results indicate that ABO-102 successfully reached target tissues throughout the body, including in the central nervous system.

  • 11

    Oct

  • 12

    Oct

  • 17

    Oct

  • 23

    Oct

ABEO Abeona Therapeutics
$18.50

1.1 (6.32%)

10/05/17
MAXM
10/05/17
NO CHANGE
MAXM
Abeona Therapeutics price target raised to $35 from $17 at Maxim
Maxim analyst Jason McCarthy says the Phase 1/2 trial of Abeona's ABO-102 drug for Sanfilippo syndrome "has demonstrated early proof of concept and positive safety." The analyst says that the risk facing the company has declined, and he raised his price target on the shares to $35 from $17 while keeping a Buy rating on the stock.
09/14/17
RBCM
09/14/17
INITIATION
Target $23
RBCM
Outperform
Abeona Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler started Abeona Therapeutics with an Outperform rating and $23 price target.
07/19/17
MAXM
07/19/17
NO CHANGE
Target $17
MAXM
Buy
Abeona Therapeutics price target raised to $17 from $14 at Maxim
Maxim analyst Jason McCarthy noted that Abeona Therapeutics announced FDA guidance for accelerating EB-101 into a Phase 3 pivotal program in epidermolysis bullosa and that the gene therapy corrected skin grafts have demonstrated proof of concept data in the early going of a Phase 1/2 study in Recessive Dystrophic Epidermolysis Bullosa patients. Factoring in the potential for a RDEB indication for EB-101, McCarthy raised his price target on Abeona to $17 from $14 and keeps a Buy rating on the stock.
03/06/17
03/06/17
NO CHANGE

FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."

TODAY'S FREE FLY STORIES

TEST

DEF Company

22:17
02/19/18
02/19
22:17
02/19/18
22:17
Recommendations
DEF Company analyst commentary  

Technical testing 2217

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:15
02/19/18
02/19
22:15
02/19/18
22:15
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change  »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:13
02/19/18
02/19
22:13
02/19/18
22:13
Upgrade
Chipotle rating change  »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:12
02/19/18
02/19
22:12
02/19/18
22:12
Upgrade
Chipotle rating change  »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change  »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change  »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change  »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change  »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TEST

DEF Company

22:01
02/19/18
02/19
22:01
02/19/18
22:01
Recommendations
DEF Company analyst commentary  

Technical testing 2201

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEST

DEF Company

21:13
02/19/18
02/19
21:13
02/19/18
21:13
Recommendations
DEF Company analyst commentary  

Technical Testing 2113

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEST

DEF Company

20:49
02/19/18
02/19
20:49
02/19/18
20:49
Recommendations
DEF Company analyst commentary  

Technical testing 2049

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEST

DEF Company

20:41
02/19/18
02/19
20:41
02/19/18
20:41
Hot Stocks
technical testing 

technical testing

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

, SNY

Sanofi

$39.91

0.19 (0.48%)

20:02
02/19/18
02/19
20:02
02/19/18
20:02
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

SNY

Sanofi

$39.91

0.19 (0.48%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNAP

Snap

$20.42

0.67 (3.39%)

GE

General Electric

$15.05

0.2 (1.35%)

DIS

Disney

$106.53

1.35 (1.28%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

HOV

Hovnanian

$2.24

0.12 (5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 18

    Mar

  • 25

    Mar

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 30

    May

  • 14

    Jul

  • 12

    Oct

CUB

Cubic

19:34
02/19/18
02/19
19:34
02/19/18
19:34
Hot Stocks
Cubic names president, CEO Bradley Feldmann as Chairman of the Board »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 14

    Jun

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:10
02/19/18
02/19
19:10
02/19/18
19:10
Earnings
Breaking Earnings news story on Hi-Crush Partners »

Hi-Crush Partners expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:08
02/19/18
02/19
19:08
02/19/18
19:08
Earnings
Hi-Crush Partners reports Q4 diluted EPS 47c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

FSS

Federal Signal

$19.40

0.15 (0.78%)

19:04
02/19/18
02/19
19:04
02/19/18
19:04
Hot Stocks
Federal Signal declares dividend of 7c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCE

BCE

$44.49

-0.02 (-0.04%)

19:03
02/19/18
02/19
19:03
02/19/18
19:03
Hot Stocks
BCE reports results of Series AC, AD Preferred Share conversions »

BCE announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PRGX

PRGX Global

$7.95

0.35 (4.61%)

18:38
02/19/18
02/19
18:38
02/19/18
18:38
Hot Stocks
PRGX Global announces appointment of new Chief Product Officer »

PRGX Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CRMT

America's Car-Mart

$46.25

0.6 (1.31%)

18:37
02/19/18
02/19
18:37
02/19/18
18:37
Earnings
America's Car-Mart reports Q3 revenue $$147M, consensus $136.24M »

Reports Q3 $1.82 per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

TAX

Liberty Tax

18:30
02/19/18
02/19
18:30
02/19/18
18:30
Hot Stocks
Liberty Tax Service taps Nicole Ossenfort to be CEO »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAX

Liberty Tax

18:29
02/19/18
02/19
18:29
02/19/18
18:29
Hot Stocks
Shaun York to be Chief Operating Officer for Liberty Tax Service »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.